CSL Response to Patent Complaint

CSL Response to Patent Complaint

Melbourne, Australia — 12/04/2017

CSL Limited (ASX:CSL; USOTC:CSLLY) has become aware that Shire ViroPharma has filed a complaint in the US District Court for the District of Delaware alleging infringement of a newly granted US patent in connection with a method of treating Hereditary Angioedema (HAE) by subcutaneously administering C1-esterase inhibitor.

FY2017 profit upgrade

CSL remains highly confident that CSL830 does not infringe any valid claim of the Shire ViroPharma patent and will vigorously defend against the claims.

In August 2016, the U.S. Food and Drug Administration (US FDA) accepted for review CSL’s Biologics License Application for CSL830, CSL’s low-volume subcutaneous C1-esterase inhibitor (human) replacement therapy for the prevention of HAE attacks. This work is the product of independent research and development work at CSL Behring.

Subject to US FDA approval, CSL is looking forward to bringing this exciting new therapy to patients later this year.

Download This Release

FURTHER INFORMATION

For further information, please contact:

Investors:
  Mark Dehring
  Head of Investor Relations
  CSL Limited
  Phone: +613 9389 3407
  Email: mark.dehring@csl.com.au
Media:
  Jemimah Pentland
  Head of Asia Pacific Communications
  CSL Limited
  Phone: +613 9389 3473
  Mobile: +61 412 635 483
  Email: jemimah.pentland@csl.com.au

© 2017 CSL Limited